DK3412660T3 - Sulfonamidderivat og farmaceutisk sammensætning indeholdende samme - Google Patents
Sulfonamidderivat og farmaceutisk sammensætning indeholdende samme Download PDFInfo
- Publication number
- DK3412660T3 DK3412660T3 DK17747622.3T DK17747622T DK3412660T3 DK 3412660 T3 DK3412660 T3 DK 3412660T3 DK 17747622 T DK17747622 T DK 17747622T DK 3412660 T3 DK3412660 T3 DK 3412660T3
- Authority
- DK
- Denmark
- Prior art keywords
- same
- pharmaceutical composition
- composition containing
- sulfonamide derivative
- sulfonamide
- Prior art date
Links
- HFFXLYHRNRKAPM-UHFFFAOYSA-N 2,4,5-trichloro-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C(=CC(Cl)=C(Cl)C=2)Cl)=N1 HFFXLYHRNRKAPM-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016021053 | 2016-02-05 | ||
| PCT/JP2017/004278 WO2017135472A1 (ja) | 2016-02-05 | 2017-02-06 | スルホンアミド誘導体及びそれを含有する医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3412660T3 true DK3412660T3 (da) | 2020-11-30 |
Family
ID=59500204
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17747622.3T DK3412660T3 (da) | 2016-02-05 | 2017-02-06 | Sulfonamidderivat og farmaceutisk sammensætning indeholdende samme |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10562898B2 (da) |
| EP (1) | EP3412660B9 (da) |
| JP (1) | JP6820282B2 (da) |
| KR (1) | KR102870086B1 (da) |
| CN (1) | CN108699008B (da) |
| AU (1) | AU2017214589B2 (da) |
| CA (1) | CA3013433A1 (da) |
| DK (1) | DK3412660T3 (da) |
| EA (1) | EA036432B1 (da) |
| ES (1) | ES2856125T3 (da) |
| HU (1) | HUE053354T2 (da) |
| MX (1) | MX381970B (da) |
| PL (1) | PL3412660T3 (da) |
| PT (1) | PT3412660T (da) |
| TW (1) | TWI730042B (da) |
| WO (1) | WO2017135472A1 (da) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE277034T1 (de) | 1998-10-26 | 2004-10-15 | Univ New York State Res Found | Liponsaürederivate und deren verwendung bei der behandlung von krankheiten |
| TWI754702B (zh) | 2016-12-28 | 2022-02-11 | 德商Ｕｃｂ製藥有限公司 | （氮雜）吲哚－和苯並呋喃－３－磺醯胺類 |
| US12582809B2 (en) | 2018-01-26 | 2026-03-24 | Bt Bidco, Inc. | Treatment of a disease of the gastrointestinal tract with a PDE4 inhibitor |
| EP3810085A1 (en) | 2018-06-20 | 2021-04-28 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an integrin inhibitor |
| KR102630416B1 (ko) | 2018-10-30 | 2024-02-01 | 길리애드 사이언시즈, 인코포레이티드 | 알파4베타7 인테그린 억제제로서의 퀴놀린 유도체 |
| AU2019373242B2 (en) | 2018-10-30 | 2023-07-13 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4 beta 7 integrin |
| ES3013256T3 (en) | 2018-10-30 | 2025-04-11 | Gilead Sciences Inc | Imidazo[1,2-a]pyridine derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases |
| US11179383B2 (en) | 2018-10-30 | 2021-11-23 | Gilead Sciences, Inc. | Compounds for inhibition of α4β7 integrin |
| CN114222730B (zh) * | 2019-08-14 | 2024-09-10 | 吉利德科学公司 | 用于抑制α4β7整合素的化合物 |
| US20230107927A1 (en) | 2020-02-28 | 2023-04-06 | First Wave Bio, Inc. | Methods of treating iatrogenic autoimmune colitis |
| MX2024004049A (es) | 2021-10-05 | 2024-04-25 | Ea Pharma Co Ltd | Metodo para producir compuesto o sal farmaceuticamente aceptable del mismo. |
| CN120882414A (zh) | 2023-04-06 | 2025-10-31 | Ea制药株式会社 | 用于治疗炎症性肠病的药物组合物 |
| CN120897744A (zh) | 2023-04-06 | 2025-11-04 | Ea制药株式会社 | 含有磺酰胺衍生物的自乳化组合物和自乳化药物递送系统 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU779063B2 (en) | 1999-12-06 | 2005-01-06 | F. Hoffmann-La Roche Ag | 4-pyridinyl-N-acyl-L-phenylalanines |
| US6388084B1 (en) | 1999-12-06 | 2002-05-14 | Hoffmann-La Roche Inc. | 4-pyridinyl-n-acyl-l-phenylalanines |
| WO2001056994A1 (en) * | 2000-02-04 | 2001-08-09 | Biogen, Inc. | Integrin antagonists |
| ATE497385T1 (de) | 2000-08-18 | 2011-02-15 | Ajinomoto Kk | Neue phenylalanin-derivate |
| EP1477482B1 (en) | 2002-02-20 | 2010-04-14 | Ajinomoto Co., Inc. | Novel phenylalanine derivative |
| JP4233353B2 (ja) | 2002-02-27 | 2009-03-04 | 田辺三菱製薬株式会社 | 医薬組成物 |
| AU2004251750A1 (en) * | 2003-06-25 | 2005-01-06 | Elan Pharmaceuticals, Inc. | Methods and compositions for treating rheumatoid arthritis |
| EP1700850B1 (en) | 2003-12-22 | 2015-07-15 | Ajinomoto Co., Inc. | Phenylalanine derivative |
| WO2005077915A1 (en) | 2004-02-10 | 2005-08-25 | Janssen Pharmaceutica, N.V. | Pyridazinones as antagonists of a4 integrins |
| EP1735000A2 (en) * | 2004-04-16 | 2006-12-27 | Genentech, Inc. | Method for augmenting b cell depletion |
| JP5231215B2 (ja) | 2005-05-20 | 2013-07-10 | イーラン ファーマスーティカルズ、インコーポレイテッド | Ｖｌａ−４アンタゴニストとしてのイミダゾロンフェニルアラニン誘導体 |
| CA2871464C (en) * | 2012-04-24 | 2017-09-26 | Ajinomoto Co., Inc. | Sulfonamide derivatives and their use in the inhibition of .alpha.4.beta.7 integrin-dependent process |
| DE102013206014A1 (de) * | 2013-04-05 | 2014-10-09 | Dürr Systems GmbH | Energiewandler-System und Baugruppen hierfür |
| ES2778200T3 (es) * | 2013-10-29 | 2020-08-10 | Ea Pharma Co Ltd | Derivado de sulfonamida y su uso medicinal |
-
2017
- 2017-02-06 AU AU2017214589A patent/AU2017214589B2/en active Active
- 2017-02-06 MX MX2018009459A patent/MX381970B/es unknown
- 2017-02-06 HU HUE17747622A patent/HUE053354T2/hu unknown
- 2017-02-06 PT PT177476223T patent/PT3412660T/pt unknown
- 2017-02-06 CN CN201780009898.0A patent/CN108699008B/zh active Active
- 2017-02-06 EP EP17747622.3A patent/EP3412660B9/en active Active
- 2017-02-06 PL PL17747622T patent/PL3412660T3/pl unknown
- 2017-02-06 JP JP2017565026A patent/JP6820282B2/ja active Active
- 2017-02-06 DK DK17747622.3T patent/DK3412660T3/da active
- 2017-02-06 US US16/075,415 patent/US10562898B2/en active Active
- 2017-02-06 KR KR1020187025805A patent/KR102870086B1/ko active Active
- 2017-02-06 CA CA3013433A patent/CA3013433A1/en active Pending
- 2017-02-06 WO PCT/JP2017/004278 patent/WO2017135472A1/ja not_active Ceased
- 2017-02-06 TW TW106103847A patent/TWI730042B/zh active
- 2017-02-06 ES ES17747622T patent/ES2856125T3/es active Active
- 2017-02-06 EA EA201891780A patent/EA036432B1/ru not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| EP3412660B1 (en) | 2020-11-18 |
| MX2018009459A (es) | 2018-09-21 |
| KR102870086B1 (ko) | 2025-10-16 |
| WO2017135472A1 (ja) | 2017-08-10 |
| TW201733991A (zh) | 2017-10-01 |
| CN108699008A (zh) | 2018-10-23 |
| CA3013433A1 (en) | 2017-08-10 |
| ES2856125T3 (es) | 2021-09-27 |
| TWI730042B (zh) | 2021-06-11 |
| MX381970B (es) | 2025-03-04 |
| AU2017214589B2 (en) | 2020-09-03 |
| KR20180104758A (ko) | 2018-09-21 |
| US10562898B2 (en) | 2020-02-18 |
| BR112018015855A2 (pt) | 2018-12-26 |
| AU2017214589A1 (en) | 2018-08-16 |
| CN108699008B (zh) | 2021-10-08 |
| PL3412660T3 (pl) | 2021-04-19 |
| PT3412660T (pt) | 2021-01-13 |
| EP3412660A4 (en) | 2019-07-10 |
| JPWO2017135472A1 (ja) | 2018-11-29 |
| EA201891780A1 (ru) | 2019-02-28 |
| EP3412660B9 (en) | 2021-04-14 |
| JP6820282B2 (ja) | 2021-01-27 |
| HUE053354T2 (hu) | 2021-06-28 |
| US20190040059A1 (en) | 2019-02-07 |
| EA036432B1 (ru) | 2020-11-10 |
| EP3412660A1 (en) | 2018-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL289276A (en) | Treprostinil derivatives and compositions and uses thereof | |
| DK3357513T3 (da) | Farmaceutisk sammensætning og anvendelse deraf | |
| DK3347472T3 (da) | Sammensætninger som indeholder cyp76ad1- clade polypeptider og anvendelse heraf. | |
| DK3452463T3 (da) | Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf | |
| EP3493799A4 (en) | CANNABIS | |
| EP3513809A4 (en) | MEDICAL COMPOSITION | |
| DK3529248T3 (da) | Farmaceutiske sammensætninger | |
| DK3655038T3 (da) | Farmaceutisk sammensætning | |
| EP3454899C0 (en) | PHARMACEUTICAL COMPOSITION | |
| DK3603620T3 (da) | Liposomsammensætning og farmaceutisk sammensætning | |
| EP3493798A4 (en) | CANNABIS | |
| EP3641771A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
| PT3500255T (pt) | Composições farmacêuticas oftálmicas e utilizações relacionadas com estas | |
| PT3412660T (pt) | Derivado de sulfonamida e composição farmacêutica contendo o mesmo | |
| DK3494119T3 (da) | Forbindelser og sammensætninger og anvendelser deraf | |
| DK3255042T3 (da) | Heterocyklisk forbindelse og farmaceutisk sammensætning omfattende samme | |
| DK3399978T3 (da) | Antiproliferative forbindelser og farmaceutiske sammensætninger dermed og anvendelser deraf | |
| DK3634377T3 (da) | Farmaceutisk formulering | |
| EP3641847A4 (en) | CLOSED VALVE | |
| DK3388085T3 (da) | Farmaceutisk sammensætning og anvendelser deraf | |
| DK3583943T3 (da) | Farmaceutisk sammensætning | |
| EP3402470A4 (en) | STABLE PHARMACEUTICAL COMPOSITION | |
| DK3383397T3 (da) | Farmaceutiske sammensætninger indeholdende doravirin, tenofovirdisoproxilfumarat og lamivudin | |
| DK4023651T3 (da) | Optisk aktivt pyranochromenylphenolderivat og farmaceutisk sammensætning, der omfatter samme | |
| SMT202400478T1 (it) | Composizione farmaceutica |